iSpecimen (NASDAQ:ISPC – Get Free Report) and DocGo (NASDAQ:DCGO – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, dividends, earnings and risk.
Analyst Ratings
This is a breakdown of current ratings and target prices for iSpecimen and DocGo, as reported by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
iSpecimen | 0 | 0 | 0 | 0 | 0.00 |
DocGo | 0 | 3 | 3 | 0 | 2.50 |
DocGo has a consensus price target of $3.56, indicating a potential upside of 110.65%. Given DocGo’s stronger consensus rating and higher possible upside, analysts clearly believe DocGo is more favorable than iSpecimen.
Risk and Volatility
Insider and Institutional Ownership
13.6% of iSpecimen shares are owned by institutional investors. Comparatively, 56.4% of DocGo shares are owned by institutional investors. 12.2% of iSpecimen shares are owned by insiders. Comparatively, 2.7% of DocGo shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Profitability
This table compares iSpecimen and DocGo’s net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
iSpecimen | -139.63% | -285.20% | -114.37% |
DocGo | -0.12% | 2.52% | 1.70% |
Valuation and Earnings
This table compares iSpecimen and DocGo”s gross revenue, earnings per share (EPS) and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
iSpecimen | $9.29 million | 0.26 | -$12.50 million | ($12.89) | -0.07 |
DocGo | $616.55 million | 0.28 | $19.99 million | ($0.02) | -84.50 |
DocGo has higher revenue and earnings than iSpecimen. DocGo is trading at a lower price-to-earnings ratio than iSpecimen, indicating that it is currently the more affordable of the two stocks.
Summary
DocGo beats iSpecimen on 11 of the 14 factors compared between the two stocks.
About iSpecimen
iSpecimen Inc. provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. Its cloud-based technology enables scientists to search for specimens and patients across a network of hospitals, clinics, private practice groups, laboratories, blood centers, biobanks, clinical research sites, and cadaveric donation centers. The company develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them. It serves biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions. iSpecimen Inc. was incorporated in 2009 and is headquartered in Lexington, Massachusetts.
About DocGo
DocGo Inc. provides mobile health and medical transportation services for various health care providers in the United States and the United Kingdom. The company's transportation services include emergency response services; and non-emergency transport services comprise ambulance and wheelchair transportation services. It also offers mobile health services through its platform that are performed at home, offices, and other locations; event services, which include on-site healthcare support at sporting events and concerts; and total care management solutions comprising healthcare services and ancillary services, such as shelter. DocGo Inc. was founded in 2015 and is headquartered in New York, New York.
Receive News & Ratings for iSpecimen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iSpecimen and related companies with MarketBeat.com's FREE daily email newsletter.